TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07693738: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Characteristics of SSGJ-716 Injection Administered Subcutaneously in Healthy Chinese Adults and Participants With Moderate-to-Severe Atopic Dermatitis

Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Phase: PHASE1 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 96 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$5,614,080

Rescue Site Savings

+$3,701,784

Unlock Full NCT07693738 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07693738 Rescue Dossier →